Navigation Links
FDA grants cardiotrophin-1 Orphan Drug status for acute liver failure treatment to Digna Biotech
Date:9/21/2011

Digna Biotech, a Spanish biotechnological company, announces that the Food and Drug Administration (FDA) granted cardiotrophin-1 (CT-1) Orphan Drug status for use in the treatment of acute liver failure (Designation request 11-3507).

This provides more incentives to work on cures for this disease, which has an incidence of 2,000 cases per year in the United States, according to the findings reported by Acute Liver Failure Study Group (ALFSG) (Lee, Squires et al. 2008). In August, the European Medicine Agency (EMA) granted also the Orphan Drug status of cardiotrophin-1 for the treatment of acute liver failure (EU/3/11/893).

Pablo Ortiz, CEO at Digna Biotech, commented, "The experimental findings that support this new indication of CT-1 are very strong and we are confident that they can be converted in a clinical valuable effect in patients suffering from acute liver failure of different etiology. Acute liver failure is a very severe condition with a high mortality rate and very limited therapeutics possibilities that needs effective treatments. The advantage of having the product at the clinical stage starting Phase I allow us to plan Phase II for this indication by the end of next year."

Acute liver failure is a rare disease that is manifested by a sudden loss of the normal liver functions in a patient with a previously normal liver and without evidence of chronic liver disease. The most common first sign of liver failure is yellowing of the skin (jaundice). This condition has serious complications such as bruising and bleeding due to impaired blood clotting as well as cerebral edema (swelling around the brain), convulsions (fits) and coma. The most common causes of acute liver failure are toxic damage (e.g. alcohol and drugs such as paracetamol) or viral hepatitis (an infectious disease that affects the liver). Acute liver failure is a long-term debilitating and life-threatening disease because of its damaging effects on the brain and other organs.

Cardiotrophin-1 is a naturally occurring chemical messenger in the blood that has antioxidant (a molecule that prevents the oxidation of other molecules) and anti-inflammatory properties. Liver cells actively produce cardiotrophin-1 as part of the defense mechanism against injury. The medicine is expected to work the same way as naturally occurring cardiotrophin-1 by acting as a messenger to the damaged liver cells, helping them to recover and restoring their function. The effects of cardiotrophin-1 have been evaluated in experimental models.

Cardiotrophin-1 is co-developed for its use in organ transplantation and tissue regeneration by Digna Biotech and Biotecnol (The Consortium). Both of the companies signed an Exclusive License and Option Agreement with Genentech, Inc. (a fully owned subsidiary of the Roche Group) in September 2009. Pre-clinical and clinical development of cardiotrophin-1 was funded by a number of private and public entities in Spain: ClaveSuan, the Center for Industrial and Technological Development (CDTI), and the Government of Navarra. Only in liver resection and transplantation, cardiotrophin-1 may generate revenues of 350 million of euros per year.


'/>"/>
Contact: Nuria Safont
nsafont@dignabiotech.com
Digna Biotech S.L
Source:Eurekalert

Related biology news :

1. EPA grants help Wayne State researchers stave off Great Lakes environmental invaders
2. CWRU School of Dental Medicine receives $2.6 million in grants
3. Lincoln Park Zoo awarded 2 significant grants for science education
4. Grants awarded to help bring promising bioscience discoveries to market
5. American Health Assistance Foundation announces latest grants for innovative vision research
6. S.L.E. Lupus Foundation announces new grants to further NYC scientists leadership in lupus research
7. Altitude Research Center wins major Pentagon grants
8. Pancreatic Cancer Action Network-AACR Pathway to Leadership Grants awarded to early-career investigators
9. Scientists awarded carcinoid tumor and pancreatic neuroendocrine tumor research grants
10. $38.4M NHMRC program grants extend cancer and blood cell research
11. NIFA announces grants to study the effects of climate change on agricultural and forest production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... Branford, CT (PRWEB) , ... March 23, 2017 ... ... Counsel, LLC, was recently selected by the Connecticut Technology Council (CTC) as a ... honored at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner ...
(Date:3/23/2017)... 2017  Agriculture technology company Cool Planet has closed ... conversion to commercialize its Cool Terra and Cool Fauna ... products that are simultaneously profitable as well as sustainable ... 18 months. This latest round of funding was led ... The company,s primary product, Cool Terra, can ...
(Date:3/22/2017)... ... 22, 2017 , ... Researchers face a fundamental challenge as ... full-size tissues, bones, even whole organs to implant in people to treat disease ... into the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t ...
Breaking Biology Technology: